⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Compare S-1 Plus Oxaliplatin to S-1 as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Compare S-1 Plus Oxaliplatin to S-1 as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer

Official Title: A Prospective,Multicentral,Open-label,Randomized,Controlled,Phase III Clinical Trial to Compare S-1 Plus Oxaliplatin to S-1 as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer

Study ID: NCT01795027

Conditions

Gastric Cancer

Study Description

Brief Summary: Background: It is shown that TS-1 as adjuvant chemotherapy after D2 resection in patients with gastric cancer can improve DFS and OS in one Japanese Trial. And TS-1 has become one of the standard therapies to these patients. But it is still unknown whether it would improve more to OS and DFS than single TS-1 after combined with oxaliplatin . This trial is designed to investigate the efficacy and safety of TS-1 plus oxaliplatin versus TS-1 single as adjuvant chemotherapy after D2 resection in patients with gastric cancer. Patients and methods: In this study , patients with histologically confirmed gastric cancer who received D2 resection and staged II or III, aged from 18 to 70 years and with Eastern Cooperative Oncology Group performance status ≤2 and adequate organ function, are randomized 1:1 to oxaliplatin 100mg/m2 on day 1 and TS-1 40\~60mg twice everyday for 14 days in a 21-days cycle for total 6 cycles followed by TS-1 single with the same dose and frequency to the end of the 1st year postoperatively(SOX) , or TS-1 single 40\~60mg twice everyday for 14 days in a 21-days cycle to the end of the 1st year postoperatively (TS-1). The primary end point is overall survival (OS), and secondary end point is disease free survival(DFS) and safety. Final study analysis will be conducted in the end of the 5th year after the last patient's enrollment.

Detailed Description:

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

the central hospital of Chaozhou, Chaozhou, Guangdong, China

the 1st people's hospital of Foshan, Foshan, Guangdong, China

cancer center of Guangzhou medical college, Guangzhou, Guangdong, China

cancer center of Sun yat-sen University, Guangzhou, Guangdong, China

Guangdong Traditional Medical Hospital, Guangzhou, Guangdong, China

the 1st affliated hospital of Guangdong pharmacuetic college, Guangzhou, Guangdong, China

the 1St Affliated Hospital of Guangzhou Medical College, Guangzhou, Guangdong, China

the 6th affliated hospital of Sun-yat-sen University, Guangzhou, Guangdong, China

the 1st hospital of Shantou University, Shantou, Guangdong, China

the cental hospital of Shantou, Shantou, Guangdong, China

YUE-BEI people's hospital, Shaoguan, Guangdong, China

the 2nd people's hospital of Shenzhen, Shenzhen, Guangdong, China

the 5th hospital of Sun-yat-sen University, Zhuhai, Guangdong, China

Contact Details

Name: Zhiwei Zhou, PHD

Affiliation: SunYat-sen University

Role: STUDY_CHAIR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: